List of Tricor drug patents
Tricor is owned by Abbvie.
Tricor contains Fenofibrate.
Tricor has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Tricor are:
- US7320802
- US7276249
Tricor was authorised for market use on 05 November, 2004.
Tricor is available in tablet;oral dosage forms.
Tricor can be used as adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v).
The generics of Tricor are possible to be released after 21 February, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320802 | ABBVIE | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(3 months ago) | |
| US7276249 | ABBVIE | Nanoparticulate fibrate formulations |
Feb, 2023
(3 months ago) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hype...
Dosage: TABLET;ORAL
TRICOR family patents
94
United States
24
Japan
17
European Union
14
Australia
14
Canada
9
Austria
8
Germany
6
Spain
4
Korea, Republic of
4
Denmark
4
Argentina
3
Cyprus
3
Portugal
3
China
3
Taiwan
2
EA
2
New Zealand
2
Uruguay
2
Norway
2
Mexico
1
Israel
1
Tunisia
1
Malaysia
1
Singapore
1
Morocco
1
Brazil
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic